Loading…
Kailera Therapeutics, Inc. is projected to decline to $20.67 by 2027, a 0% move from its current price of $20.68. KLRA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $19.92 | $20.68 | $21.47 | 0.00% |
| Jul 15 | $19.61 | $20.68 | $21.81 | 0.00% |
| Jul 16 | $19.38 | $20.68 | $22.07 | 0.00% |
| Jul 17 | $19.19 | $20.68 | $22.29 | +0.01% |
| Jul 18 | $19.02 | $20.68 | $22.49 | +0.01% |
| Jul 19 | $18.87 | $20.68 | $22.67 | +0.01% |
| Jul 20 | $18.73 | $20.68 | $22.84 | +0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $18.73 | $20.68 | $22.84 | +0.01% |
| Week 2 | $17.98 | $20.68 | $23.80 | +0.02% |
| Week 3 | $17.42 | $20.69 | $24.56 | +0.03% |
| Week 4 | $16.97 | $20.69 | $25.23 | +0.04% |
| Week 5 | $16.57 | $20.69 | $25.83 | +0.04% |
| Week 6 | $16.23 | $20.69 | $26.38 | +0.05% |
| Week 7 | $15.92 | $20.69 | $26.90 | +0.06% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules.
Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Kailera Therapeutics, Inc. (KLRA) is a healthcare stock currently priced at $21.01 per share. It has a market capitalization of $2.72B and is ranked 1839 by market cap.
The current price and market position reflect a biotechnology issuer focused on obesity-related metabolic diseases with a diverse pipeline across injectable and oral formats. The forecast suggests a path to higher prices over the next several years, with year-by-year averages indicating growth from 2026 through 2050 and bullish sentiment emerging in later years.
From 2026 to 2050, the predicted average prices rise at multiple steps, with notable gains by 2029 onward and a long-run peak indicated in 2050. The 2050 forecast presents an average of $81.81 and a max of $188.16, pointing to a substantial longer-term upside despite periodic fluctuations.
A major floor 22.2% below — a decisive break under it would weaken the trend.
The nearest floor, 10.3% below — buyers have tended to step in here.
The nearest ceiling, 12.7% above — a clean break opens room to run.
A major ceiling 25.7% above — clearing it would confirm fresh momentum.
Key KLRA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KLRA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $21.80 | Sell | $21.35 | Sell |
| MA 10 | $21.63 | Sell | $21.42 | Sell |
| MA 20 | $20.91 | Sell | $21.29 | Sell |
| MA 50 | $21.56 | Sell | $21.85 | Sell |
| MA 100 | — | Neutral | — | Neutral |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.66 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -14.92 | Neutral |
| Williams %R (14) | -99.24 | Info |
| MACD (12,26,9) | 0.07 | Buy |
| ROC (12) | -3.23 | Sell |
| Bollinger %B (20,2) | 0.45 | Neutral |
| Stochastic %K (14) | 0.76 | Buy |
| TRIX (15) | 0.00 | Buy |
| Awesome (5,34) | 0.71 | Buy |
| Ultimate (7,14,28) | 44.02 | Neutral |
| Momentum (10) | 0.02 | Buy |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 21.29 | Sell |
| ADX (14) | 11.95 | Neutral |
| ATR (14) | 0.79 | Info |
The 30-day technical picture is NEUTRAL. RSI14 sits at 50, and the stock trades around the 50-day moving average of $21.62, with no value provided for the 200-day SMA.
Key near-term levels show support at $18.55 and resistance at $23.30. The 30-day range spans from a low of $16.28 to a high of $27.11, indicating a broad trading window over the coming month.
Annualized volatility is high at 70, underscoring elevated near-term price movement potential as traders weigh the stock’s clinical-stage risk profile against growth expectations.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $18.55 | $20.68 | $27.93 | 0% | Neutral | |
| $14.84 | $20.67 | $31.15 | 0% | Neutral | |
| $15.07 | $22.39 | $36.06 | +8% | Neutral | |
| $16.62 | $26.12 | $44.24 | +26% | Bullish | |
| $18.12 | $29.96 | $52.89 | +45% | Bullish | |
| $15.82 | $27.42 | $50.18 | +33% | Bullish | |
| $14.29 | $25.93 | $48.97 | +25% | Bullish | |
| $15.13 | $28.69 | $55.75 | +39% | Bullish | |
| $13.68 | $27.08 | $54.00 | +31% | Bullish | |
| $15.50 | $32.02 | $65.37 | +55% | Bullish | |
| $15.51 | $34.46 | $77.54 | +67% | Bullish | |
| $34.90 | $77.55 | $178.37 | +275% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $18.55 | $20.68 | $24.55 | +0.00% |
| August 2026 | $16.27 | $19.75 | $25.00 | -4.50% |
| September 2026 | $16.80 | $20.70 | $26.79 | +4.84% |
| October 2026 | $16.78 | $20.95 | $27.60 | +1.17% |
| November 2026 | $16.08 | $20.30 | $27.16 | -3.09% |
| December 2026 | $16.14 | $20.59 | $27.93 | +1.44% |
Click any year to see its month-by-month KLRA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect KLRA to range from $18.55 to $27.93 through 2026. The $20.68 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The KLRA price prediction for 2027 points to an average of $20.67 (low $14.84, high $31.15) — a potential decline of 0% on today's $20.68. Price action looks broadly range-bound.
In 2028, KLRA is projected to trade between $15.07 and $36.06, averaging $22.39 — a potential gain of +8% from today's $20.68. That is up +8% on the projected 2027 average. A consolidation phase looks the most probable path here.
Kailera Therapeutics, Inc.'s 2029 outlook centres on $26.12, within a $16.62 to $44.24 range. That is up +17% on the projected 2028 average. That marks a +26% change versus current levels. Momentum favours further upside here.
By 2030, KLRA could reach as high as $52.89, with a base case around $29.96 and support toward $18.12 — roughly +45% from $20.68. Buyers look set to stay in control over this stretch.
Expect KLRA to range from $15.82 to $50.18 through 2031. The $27.42 average target implies a +33% move from current prices. That is -8% versus the projected 2030 average. Momentum favours further upside here.
The KLRA price prediction for 2032 points to an average of $25.93 (low $14.29, high $48.97) — a potential gain of +25% on today's $20.68. Buyers look set to stay in control over this stretch.
In 2033, KLRA is projected to trade between $15.13 and $55.75, averaging $28.69 — a potential gain of +39% from today's $20.68. That is up +11% on the projected 2032 average. Momentum favours further upside here.
Kailera Therapeutics, Inc.'s 2034 outlook centres on $27.08, within a $13.68 to $54.00 range. That is -6% versus the projected 2033 average. That marks a +31% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, KLRA could reach as high as $65.37, with a base case around $32.02 and support toward $15.50 — roughly +55% from $20.68. Momentum favours further upside here.
Expect KLRA to range from $15.51 to $77.54 through 2040. The $34.46 average target implies a +67% move from current prices. That is up +8% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The KLRA price prediction for 2050 points to an average of $77.55 (low $34.90, high $178.37) — a potential gain of +275% on today's $20.68. Momentum favours further upside here.
Investing $1,000 in KLRA today (≈ 48.355899 KLRA) could be worth
$3,750.12
+$2,750.12 (+275%) by 2050 · US Dollar
Based on the average projected KLRA price of $77.55 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KLRAwould be worth at today's price.
$1,000 invested in KLRA on Apr 17, 2026 (≈ 38.461538 KLRA) would be worth
$795.38
-$204.62 (-20.5%) today · 0.80× · US Dollar
Based on a KLRA entry price of $26 vs. today's $20.68.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $21.99 | $940.43 | -6.0% |
| 1 month ago | $19.14 | $1,080.46 | +8.0% |
| All time ago | $26 | $795.38 | -20.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KLRA forecast.
Our base-case forecast reaches $41.00 around 2050.
Implied market cap at $41.00: $5.31B
The multi-year forecast envisions a bullish trend extending from the late 2020s into the 2030s and beyond. In 2029 the average price is forecast at $27.22 with ROI 29.6 and sentiment BULLISH, followed by 2030 with avg $30.97 and ROI 47.4 and sentiment BULLISH. The trajectory continues through 2035 (avg $33.64, ROI 60.1, BULLISH) and into 2040 (avg $35.72, ROI 70, BULLISH).
By 2050 the forecast shows an avg of $81.81 and a max of $188.16 with ROI 289.4 and sentiment BULLISH. Throughout this horizon, the model depicts rising price levels alongside sustained bullish projections, though it also notes that these are estimates and not guarantees.
Overall, the outlook signals meaningful upside potential over the long term while acknowledging the inherent uncertainty and the possibility of downside moves driven by broader market factors and clinical-stage execution risk.
Tap a question to reveal the answer.
In 2030, the forecast shows a min of $18.47, an avg of $30.97, and a max of $55.30, with ROI 47.4 and sentiment BULLISH.
Forecasts indicate bullish sentiment from 2029 onward, with 2029 avg $27.22, ROI 29.6; 2030 avg $30.97, ROI 47.4; 2035 avg $33.64, ROI 60.1; 2040 avg $35.72, ROI 70; and 2050 avg $81.81, ROI 289.4.
Yes—the 2050 max forecast is $188.16.
Current price is $21.01 and market cap is $2.72B.
The 30-day range is low $16.28 to high $27.11.
Kailera Therapeutics, Inc. Community Discussion
0Share your Kailera Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.